Jazz Pharma

Forecast & Rating20 analysts currently cover Jazz Pharma, with about 90.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $281.35, about 11.2% upside from the current price of $253.07. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 17.3% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Jazz Pharma closely still see room for the stock to rise. Data as of Aug 14, 2026; for reference only and not investment advice.